Glycosylation.
The majority of candidate recombinant therapeutics are glycoproteins. Four aspects of glycobiology are requisite if the full potential of such reagents is to be realised: an understanding of glycan biosynthesis and its regulation, rapid and sensitive oligosaccharide analytical techniques, determination of structure-function relationships in protein-linked carbohydrate; and manufacturing systems where product glycosylation is manipulable and consistent. The past year has seen significant progress in all of these areas, exemplified by the approval of glycosylation-engineered glucocerebrosidase for clinical use in replacement therapy of Gaucher's disease.
Warren
C E
CE
Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Canada.
D000595:Amino Acid Sequence; D000818:Animals; D001709:Biotechnology; D002240:Carbohydrate Sequence; D006023:Glycoproteins / Q000096:biosynthesis* / Q000737:chemistry / Q000235:genetics; D006031:Glycosylation; D006801:Humans; D008969:Molecular Sequence Data; D009844:Oligosaccharides / Q000737:chemistry; D015202:Protein Engineering; D011994:Recombinant Proteins / Q000096:biosynthesis / Q000737:chemistry / Q000235:genetics
D006023:Glycoproteins; D009844:Oligosaccharides; D011994:Recombinant Proteins